News
-
-
COMMUNIQUÉ DE PRESSE
H2APEX generated strong revenue growth in Q1 2024 and confirms revenue guidance for FY 2024 of EUR 35 million to EUR 40 million
H2APEX reports strong revenue growth in Q1 2024, doubling to EUR 10.1 million. Confirms revenue guidance of EUR 35-40 million for FY 2024. Expansion plans and operations are on track -
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury
bioMérieux receives FDA 510(k) clearance of VIDAS TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury, improving patient outcomes. The test uses biomarkers to predict absence of acute intracranial lesions -
COMMUNIQUÉ RÉGLEMENTÉ
bioMérieux obtient l'agrément 510(k) de la FDA pour le test innovant VIDAS® TBI (GFAP, UCH-L1), visant à améliorer l’évaluation des patients victimes d'un traumatisme crânien léger
bioMérieux obtient l'agrément 510(k) de la FDA pour le test VIDAS® TBI (GFAP, UCH-L1) améliorant l'évaluation des traumatismes crâniens légers -
-
-
COMMUNIQUÉ DE PRESSE
Super Duper Publications Announces Partnership With Coviu to Empower Speech-Language Pathologists With Enhanced Teletherapy Solutions
Super Duper Publications partners with Coviu to enhance teletherapy for SLPs by integrating educational resources. Collaboration aims to improve therapy sessions by leveraging innovative materials
